Literature DB >> 17720345

Subdural effusion in a CNS involvement of systemic juvenile xanthogranuloma: a case report treated with vinblastin.

Stéphane Auvin1, Jean-Christophe Cuvellier, Mathieu Vinchon, Sabine Defoort-Dhellemes, Gustavo Soto-Ares, Brigitte Nelken, Louis Vallée.   

Abstract

Juvenile xanthogranuloma (JXG) is one of the most common non-Langerhans cell histiocytosis in children. Usually cutaneous, there are disseminated forms. However, neurological localization remains exceptional. A 7-month-old boy had been admitted for subdural effusion due to non-accidental head injury and skin nodular lesions. A biopsy of a skin lesion was considered suggestive of JXG. Skin, eyes, brain, lungs, liver, and testicles were involved. Systemic treatment of JXG was begun with vinblastine. It allowed the regression of skin, lung, and CNS lesions. At age of 11 years, he had not reappearance of the xanthogranuloma. This report emphasizes the possible presentation of xanthogranuloma with subdural effusions, the organs which should be examined in case of disseminated forms and the efficiency of vinblastin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720345     DOI: 10.1016/j.braindev.2007.07.004

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

1.  Multimodel MRI features of an intracranial juvenile Xanthogranuloma.

Authors:  Jingkai Su; Ni Chen; Qiang Yue; Weina Wang; Simin Zhang; Xiaorui Su
Journal:  Childs Nerv Syst       Date:  2019-02-28       Impact factor: 1.475

Review 2.  Fatal juvenile xanthogranuloma presenting as a sellar lesion: case report and literature review.

Authors:  Sherise D Ferguson; Steven G Waguespack; Lauren A Langford; Joann L Ater; Ian E McCutcheon
Journal:  Childs Nerv Syst       Date:  2014-12-12       Impact factor: 1.475

3.  Imaging Features of Juvenile Xanthogranuloma of the Pediatric Head and Neck.

Authors:  D T Ginat; S O Vargas; V M Silvera; M S Volk; B A Degar; C D Robson
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-07       Impact factor: 3.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.